These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32785890)

  • 1. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
    Gonzalez-Latapi P; Bhowmick SS; Saranza G; Fox SH
    CNS Drugs; 2020 Oct; 34(10):1025-1044. PubMed ID: 32785890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
    Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
    J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide in the treatment of Parkinson's disease.
    Schapira AH
    Expert Opin Pharmacother; 2010 Sep; 11(13):2261-8. PubMed ID: 20707760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Istradefylline for the treatment of Parkinson's disease.
    Park A; Stacy M
    Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapy of the motor symptoms in the advanced stage of Parkinson's disease.
    Takahashi K
    Nihon Rinsho; 2017 Jan; 75(1):77-82. PubMed ID: 30566298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.